Format

Send to

Choose Destination
Clin Infect Dis. 2002 Nov 15;35(10):1258-62. Epub 2002 Oct 23.

Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting.

Author information

1
Department of Medicine, University of California, San Francisco, USA.

Abstract

In light of current interest in recombinant human growth hormone (GH) as a treatment for fat distribution abnormalities, we retrospectively evaluated regional changes in fat and lean body mass in a subset of subjects who participated in randomized, double-blind, placebo-controlled trials of GH for treatment of wasting. Treatment with a pharmacologic dose of GH (0.1 mg/kg/day) resulted in significant and sustained increases in lean body mass and losses of fat in both the trunk and appendicular regions.

PMID:
12410487
DOI:
10.1086/343051
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center